BOLT Bolt Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%
Returns
ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $5,000 | $26,000 | $2.50M | $2.17M | $1.80M | $1.22M | $0 |
| R&D expense | $2.21M | $4.72M | $5.25M | $4.99M | $6.54M | $7.50M | $9.51M | $11.72M |
| SG&A expense | $2.52M | $2.42M | $2.80M | $3.12M | $3.34M | $3.52M | $3.83M | $3.95M |
| Operating income | -$4.73M | -$7.95M | -$8.03M | -$7.08M | -$7.70M | -$9.21M | -$12.12M | -$16.92M |
| Net income | -$4.42M | -$7.46M | -$7.67M | -$6.63M | -$7.14M | -$8.56M | -$11.04M | -$15.94M |
| EBITDA | -$4.63M | -$7.75M | -$7.82M | -$6.83M | -$7.40M | -$8.91M | -$11.72M | -$16.49M |
| EPS (basic) | -2.25 | -3.88 | -3.99 | — | -3.72 | -4.46 | -5.76 | — |
| EPS (diluted) | -2.25 | -3.88 | -3.99 | — | -3.72 | -4.46 | -5.76 | — |
| Weighted avg. shares (diluted) | 1.97M | 1.92M | 1.92M | — | 1.92M | 1.92M | 1.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.78M | $12.86M | $11.61M | $11.70M | $17.75M | $9.60M | $8.39M | $7.21M |
| Short-term investments | $1.02M | $4.74M | $11.28M | $15.80M | $14.16M | $25.17M | $30.45M | $40.12M |
| Current assets | $17.08M | $20.56M | $25.75M | $30.26M | $35.61M | $38.34M | $42.51M | $50.81M |
| PP&E, net | $341,000 | $408,000 | $1.04M | $1.25M | $1.50M | $1.72M | $2.06M | $3.14M |
| Total assets | $35.59M | $40.18M | $48.03M | $56.75M | $65.05M | $75.50M | $85.86M | $99.63M |
| Current liabilities | $8.31M | $7.87M | $7.77M | $8.44M | $9.97M | $12.31M | $13.56M | $15.86M |
| Total liabilities | $27.03M | $27.70M | $28.63M | $30.24M | $32.95M | $36.66M | $39.05M | $42.43M |
| Shareholders' equity | $8.56M | $12.48M | $19.40M | $26.50M | $32.10M | $38.84M | $46.81M | $57.20M |
| Shares outstanding | 2.15M | 1.93M | 1.92M | 1.92M | 1.92M | 1.92M | 38.34M | 1.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.08M | -$6.54M | -$8.02M | -$7.16M | -$9.73M | -$9.60M | -$13.37M | -$14.43M |
| Capital expenditure | $0 | — | — | $0 | $72,000 | — | — | $0 |
| Free cash flow | -$3.08M | — | — | -$7.16M | -$9.80M | — | — | -$14.43M |
| Investing cash flow | $4.00M | $7.77M | $7.92M | $1.07M | $17.88M | $10.79M | $14.55M | $12.23M |
| Financing cash flow | $0 | $19,000 | $6,000 | $5,000 | $0 | $14,000 | $0 | $29,000 |
| Depreciation & amortization | $100,000 | $200,000 | $203,000 | $255,000 | $300,000 | $300,000 | $399,000 | $426,000 |
| Stock-based compensation | $506,000 | $552,000 | $545,000 | $1.04M | $407,000 | $625,000 | $709,000 | $1.18M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.